Amneal Pharmaceuticals, Inc.

AMRX - CIK 0001723128

Market cap$4.88 B

Rank#1399

SEC filings664

Amneal Pharmaceuticals, Inc. trades as AMRX and has a market capitalization of $4.88 B, making it the #1399 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.02B, up 8.0% from the prior year and net income of $72.06M. This page tracks Amneal Pharmaceuticals, Inc. through 664 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$3.02BFY 2025

Net income (latest FY)$72.06MFY 2025

Operating cash flow (latest FY)$339.99MFY 2025

Total assets (latest FY)$3.68BFY 2025

Gross margin36.9%latest FY

Net margin2.4%latest FY

Financial performance

Over the last 9 fiscal years Amneal Pharmaceuticals, Inc.'s revenue grew from $1.02B to $3.02B, a compound annual growth rate of 12.8%. Net profit margin expanded from 0.0% to 2.4% over the same period - every figure below comes from the company's audited annual filings.

AMRX annual revenueView details

Key statistics

Market cap: $4.88 B
Share price (derived)market cap / shares outstanding: $15.31
P/E ratio (trailing FY): 67.8
EPS (diluted)FY 2025: $0.22
Shares outstandingas of 2026-04-30: 0.32B
Long-term debtas of 2026-03-31: $2.57B
Cash & equivalentsas of 2026-03-31: $197.66M
Dividends paidFY 2020: $0.00

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-12
Insider sale notice	144	2026-05-11
Insider trade	4	2026-05-08
Insider trade	4	2026-05-08
Insider trade	4	2026-05-08
Insider trade	4	2026-05-08
Insider trade	4	2026-05-08
Insider trade	4	2026-05-08

Browse the full filing history (664 filings)

Recent press releases

Amneal Reports First Quarter 2026 Financial Results2026-05-07
Amneal Pharmaceuticals, Inc. - Amneal Reports First Quarter 2026 Financial Results
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.2026-04-14
Amneal Pharmaceuticals, Inc. - Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%2026-04-09
Amneal Pharmaceuticals, Inc. - Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month2026-04-07
Amneal Pharmaceuticals, Inc. - Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
Amneal to Report First Quarter 2026 Results on May 1, 20262026-04-07
A founder-led culture of redefining what's possible

Similar companies

The largest companies sharing Amneal Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T AMRX vs LLY

JNJJohnson & Johnson$573.98 B AMRX vs JNJ

ABBVAbbVie Inc.$399.47 B AMRX vs ABBV

MRKMerck & Co., Inc.$293.16 B AMRX vs MRK

AZNAstraZeneca PLC$286.27 B AMRX vs AZN

Frequently asked questions

What is Amneal Pharmaceuticals, Inc.'s market cap?

Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $4.88 B as of 2026-06-10, ranking #1399 among US-listed companies.

How much revenue does Amneal Pharmaceuticals, Inc. make?

Amneal Pharmaceuticals, Inc. reported revenue of $3.02B for fiscal year 2025, an increase of 8.0% year over year.

Is Amneal Pharmaceuticals, Inc. profitable?

Yes. Amneal Pharmaceuticals, Inc. reported net income of $72.06M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.